Ubiquinol is the reduced, electron-rich form of coenzyme Q10, a lipid-soluble quinone compound that occurs naturally in human tissues and foods and has been studied in humans for bioavailability, cardiovascular function, fatigue, exercise physiology, neurological disorders, metabolic markers, and male reproductive outcomes (Review).

Ubiquinol research overlaps with the broader coenzyme Q10 literature, but several human trials have specifically used reduced-form CoQ10 rather than ubiquinone (Research). The strongest ubiquinol-specific human evidence is concentrated in absorption studies, fatigue-related trials, exercise physiology, cardiovascular endothelial-function research, neurological pilot trials, and male fertility studies (Research) (Research). Overall confidence is limited to moderate because many studies are small, short, population-specific, or use different formulations and outcomes (Review).

Ingredient Identity

• Official name(s): Ubiquinol; reduced coenzyme Q10.
• Synonyms: Reduced CoQ10; ubiquinol-10; reduced ubiquinone.
• Classification: Lipid-soluble quinone-related compound and reduced form of coenzyme Q10 (Review).
• CAS number: Not included in the locked evidence library.
• Endogenous vs exogenous: Ubiquinol is part of the endogenous coenzyme Q10 redox system and can also be consumed through foods or supplemental preparations (Review).

Ingredient Snapshot

• Classification: Ubiquinol is the reduced form of coenzyme Q10 and participates in the broader CoQ10 redox pair with ubiquinone (Review).
• Endogenous vs exogenous status: It occurs endogenously in human tissues and is also available through food exposure and oral supplementation (Review).
• Primary human research domains: Human studies have examined fatigue, exercise physiology, cardiovascular function, neurological disorders, metabolic markers, male reproductive outcomes, and critical illness contexts (Research) (Research).
• Common study formats: The human literature includes randomized controlled trials, pilot trials, crossover studies, bioavailability studies, and open-label or smaller clinical studies (Research) (Research).
• Pharmacokinetic characterization status: Ubiquinol has human absorption and high-dose pharmacokinetic data, but formulation differences make simple dose-to-blood-level comparisons difficult (Research) (Review).
• Regulatory context (U.S./EU): In the United States, products marketed as dietary supplements are regulated under FDA’s dietary-supplement framework rather than as ordinary drugs (FDA). In the European Union, EFSA evaluated proposed coenzyme Q10 health claims and did not establish the submitted claims as authorized health claims based on the evidence reviewed (EFSA).
• Evidence maturity: The evidence base is limited to moderate, with stronger pharmacokinetic and biomarker evidence than long-term clinical-outcome evidence (Review).

Introduction

Ubiquinol is the reduced form of coenzyme Q10, meaning it is the electron-rich form of the CoQ10 molecule in the body’s redox system (Review). CoQ10 occurs in human tissues and foods, and ordinary dietary intake is much lower than doses used in many ubiquinol supplementation studies (Review).

People commonly look up ubiquinol because it is studied in areas involving mitochondrial biology, fatigue, exercise performance, cardiovascular physiology, neurological conditions, metabolic markers, and male reproductive outcomes (Review). Interest in ubiquinol also comes from formulation and absorption research suggesting that reduced-form CoQ10 may produce different blood exposure than ubiquinone in some human studies (Research).

This article is informational only, describes ubiquinol as a biochemical substance studied in human research, and does not provide medical or dosing advice.

Quick Summary

• Ubiquinol is the reduced form of coenzyme Q10, a lipid-soluble compound involved in the body’s CoQ10 redox system and studied in several human research areas (Review).
• Ubiquinol-specific human studies include absorption trials, fatigue studies, exercise trials, cardiovascular studies, neurological trials, metabolic research, and male fertility studies (Research) (Research).
• The most consistent ubiquinol-specific research base is not for a single disease claim, but for bioavailability, blood CoQ10 status, and short-to-medium-term physiological outcomes (Research) (Review).
• Fatigue-related trials reported improvements in subjective or functional measures in chronic fatigue syndrome and mild-fatigue populations, but these studies were relatively limited in size and duration (Research) (Research).
• Cardiovascular studies have examined endothelial function and heart-failure outcomes, but findings should be interpreted cautiously because several trials were pilot, short-term, or used combination designs (Research) (Research).
• Ubiquinol absorption and response vary by formulation, baseline status, population, and study design, which helps explain why results are not uniform across trials (Review).
• U.S. supplement products containing ubiquinol fall under FDA dietary-supplement regulation, while disease-treatment claims can trigger drug-like regulatory concerns (FDA) (FDA).

Human Research Findings by Condition

Cardiovascular Health

Human research on Cardiovascular Health has included endothelial-function studies and heart-failure trials using ubiquinol-specific interventions (Research) (Research). The evidence is clinically interesting but still limited because several studies used small samples, pilot designs, or short follow-up periods (Review).

Key human study

Dose studied: 400 mg/day
Population: Patients with heart failure with reduced ejection fraction
Duration: 3 months

Researchers studied oral ubiquinol in a crossover pilot study of patients with heart failure with reduced ejection fraction, focusing on peripheral endothelial function as a vascular outcome (Research). The study reported improvement in endothelial-function measures, but the pilot design limits certainty about broader clinical outcomes (Research).

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: 600 mg/day ubiquinol, with and without D-ribose
Population: Adults aged 50 years or older with heart failure with preserved ejection fraction
Duration: 12 weeks

A phase 2 randomized trial studied ubiquinol, D-ribose, their combination, and placebo in heart failure with preserved ejection fraction (Research). The study reported improvements in several symptom and cardiac markers, but not in 6-minute walk distance, which makes the overall signal mixed rather than uniformly positive (Research).

Result: Human clinical studies reported mixed findings
Evidence strength: Moderate
Study source: (Research)

Muscle Health

Human research on Muscle Health has examined exercise performance, peak power, and biochemical responses to strenuous exercise (Research) (Research). Findings vary by population and endpoint, with some trials reporting performance or oxidative-stress changes and reviews noting that exercise results are not uniform across CoQ10 studies (Review).

Key human study

Dose studied: 300 mg/day
Population: Young healthy elite trained athletes
Duration: 6 weeks

A double-blind placebo-controlled study evaluated ubiquinol supplementation in elite trained athletes and measured physical performance outcomes (Research). The study reported a statistically significant improvement in maximum power output compared with placebo, but the population was highly specific and does not represent all exercise settings (Research).

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: 200 mg/day
Population: Healthy adults exposed to strenuous exercise
Duration: 2 weeks before exercise challenge

A human trial evaluated ubiquinol before strenuous exercise and measured oxidative-stress and nitric-oxide-related markers (Research). The study reported reduced oxidative-stress markers and increased plasma nitric oxide, but these are short-term physiological markers rather than long-term performance or health outcomes (Research).

Result: Human studies observed short-term physiological effects
Evidence strength: Limited
Study source: (Research)

Stress

Human studies relevant to Stress have mainly evaluated fatigue, autonomic nervous system measures, and cognitive-fatigue loading rather than psychological stress as a standalone diagnosis (Research) (Research). The evidence is best described as limited and condition-specific because the studies used defined fatigue populations or fatigue-loading models rather than broad stress populations (Review).

Key human study

Dose studied: 150 mg/day
Population: People with chronic fatigue syndrome
Duration: 12 weeks

A randomized controlled trial studied ubiquinol-10 in chronic fatigue syndrome and assessed autonomic nervous system and cognitive-function measures (Research). The trial reported improvements in several measured outcomes, but the condition-specific population and limited study base make the evidence preliminary (Research).

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: 100 mg/day and 150 mg/day
Population: Healthy individuals with mild fatigue
Duration: Measurements during intake at 4-week intervals

A double-blind placebo-controlled study evaluated ubiquinol-10 in healthy people with mild fatigue and used cognitive-fatigue loading with subjective fatigue and sleepiness measures (Research). The study reported improvements in subjective fatigue-related measures, but the endpoints were short-term and subjective rather than disease-specific outcomes (Research).

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Neurological Health

Human research on Neurological Health has included Parkinson’s disease and multiple system atrophy trials using ubiquinol-specific interventions (Research) (Research). The evidence remains limited because the studies are exploratory, disease-specific, and not sufficient to establish clinical use (Review).

Key human study

Dose studied: 300 mg/day
Population: People with Parkinson’s disease with wearing-off
Duration: 48–96 weeks

A randomized double-blind pilot trial evaluated ubiquinol-10 in Parkinson’s disease patients with wearing-off symptoms (Research). The trial reported improvement in UPDRS scores in a small pilot setting, but the evidence remains preliminary because it was not a large confirmatory trial (Research).

Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)

Additional human study

Dose studied: 1,500 mg/day
Population: People with multiple system atrophy
Duration: Multicenter phase 2 trial period

A multicenter randomized phase 2 trial studied high-dose ubiquinol in multiple system atrophy (Research). The study helps define neurological research interest and high-dose clinical feasibility, but the evidence remains disease-specific and not broadly generalizable (Research).

Result: Human clinical studies reported mixed findings
Evidence strength: Emerging
Study source: (Research)

Diabetes and Glycemic Control

Human research on Diabetes and Glycemic Control includes a ubiquinol-specific randomized trial in adults with type 2 diabetes (Research). The evidence is limited because this domain has fewer ubiquinol-specific trials than broader CoQ10 research, and metabolic outcomes may depend on baseline health, medication status, and formulation (Review).

Key human study

Dose studied: 100 mg/day
Population: Adults with type 2 diabetes
Duration: Trial duration not fully detailed in the locked summary source

A double-blind randomized placebo-controlled trial studied liquid ubiquinol in adults with type 2 diabetes and measured glucose, lipid, and antioxidant-capacity outcomes (Research). The trial reported effects on HbA1c and antioxidant enzyme activity measures, but the ubiquinol-specific evidence base in diabetes remains relatively small (Research).

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Men’s Health

Human research on Men’s Health has focused mainly on male infertility and semen-parameter outcomes in men with abnormal sperm measures (Research) (Research). Results are promising at the biomarker level, but fertility-related outcomes require cautious interpretation because semen parameters do not always translate directly into live-birth outcomes (Research).

Key human study

Dose studied: 200 mg/day
Population: Men with unexplained oligoasthenoteratozoospermia
Duration: Trial duration not restated in the locked evidence report

A human study evaluated ubiquinol in men with unexplained oligoasthenoteratozoospermia and measured sperm density, motility, and morphology (Research). The study reported improvements in semen parameters, but the evidence is most directly about laboratory sperm measures rather than definitive fertility outcomes (Research).

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: 150 mg/day
Population: Oligoasthenozoospermic infertile men
Duration: Trial duration not restated in the locked evidence report

A study in oligoasthenozoospermic infertile men evaluated ubiquinol for semen parameters and serum testosterone (Research). The findings support continued research into male reproductive biomarkers, but the clinical evidence remains limited and population-specific (Research).

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Immune System

Human research under Immune System is limited for ubiquinol and is mostly represented by a pilot study in severe sepsis or septic shock rather than routine immune-support research (Research). Because sepsis is an acute critical illness, this evidence should not be generalized to everyday immune function (Research).

Key human study

Dose studied: 200 mg enteral ubiquinol twice daily
Population: Patients with severe sepsis or septic shock
Duration: Pilot trial context

A randomized pilot trial evaluated enteral ubiquinol in severe sepsis or septic shock (Research). The study provides early evidence in critical illness, but it was not a broad immune-health trial and should be interpreted as exploratory (Research).

Result: Human evidence remains limited or inconclusive
Evidence strength: Emerging
Study source: (Research)

Dosage & Study Snapshot (Research Context)

Human ubiquinol research includes ordinary dietary CoQ10 exposure, lower-dose supplemental studies, moderate-dose clinical trials, high-dose neurological studies, and pharmacokinetic or formulation-specific studies (Review) (Research). Dietary exposure is much lower than supplemental trial doses, and formulation differences are important because CoQ10 absorption is lipid-dependent and varies across preparations (Review).

Approximately 3–6 mg/day dietary CoQ10 exposure:

Average dietary CoQ10 intake has been described as approximately 3–6 mg/day, which is far below most ubiquinol supplement trials (Review). This exposure comes from foods rather than purified ubiquinol supplements, so it provides natural-occurrence context rather than an intervention dose (Review). Foods such as meat, fish, nuts, and some oils contain CoQ10, while many fruits, vegetables, cereals, and dairy foods generally contribute lower amounts (Review). This band matters because it shows that clinical-trial ubiquinol doses are usually much higher than ordinary dietary exposure (Review).

Result: Observational association
Evidence strength: Observational
Notes / limitations: This is dietary CoQ10 context, not a controlled ubiquinol supplementation trial.

90–300 mg/day oral ubiquinol:

A healthy-adult safety and bioavailability study evaluated single and repeated oral ubiquinol exposure, including repeated 90–300 mg/day dosing over 4 weeks (Research). Researchers measured absorption and safety-related outcomes rather than disease endpoints (Research). This range is important because it anchors the lower end of the ubiquinol-specific supplementation evidence in healthy adults (Research). It also shows that early ubiquinol research focused heavily on blood exposure and tolerability before broader clinical outcomes (Research).

Result: Preliminary signal
Evidence strength: Limited
Notes / limitations: This dose band primarily supports absorption and short-term safety context.

100 mg/day liquid ubiquinol:

A double-blind randomized placebo-controlled trial studied 100 mg/day liquid ubiquinol in adults with type 2 diabetes (Research). The study measured glucose, lipid, and antioxidant-capacity outcomes, including HbA1c and antioxidant enzyme activity measures (Research). The liquid formulation matters because ubiquinol bioavailability can vary by delivery system and lipid-based preparation (Review). This dose band is one of the lower clinical metabolic-study exposures in the locked evidence library (Research).

Result: Modest improvement
Evidence strength: Limited
Notes / limitations: The evidence is specific to type 2 diabetes and a liquid ubiquinol formulation.

100–150 mg/day ubiquinol-10:

A double-blind placebo-controlled study in healthy individuals with mild fatigue evaluated 100 mg/day and 150 mg/day ubiquinol-10 (Research). Researchers assessed subjective fatigue and sleepiness after cognitive-fatigue loading, with serum ubiquinol also measured (Research). This dose band is relevant because it links relatively low supplemental ubiquinol exposures to fatigue-related outcomes in otherwise healthy adults (Research). The findings are useful for research context but remain limited by subjective endpoints and population specificity (Research).

Result: Modest improvement
Evidence strength: Limited
Notes / limitations: Outcomes were fatigue-related measures, not broad disease endpoints.

150 mg/day oral ubiquinol-10:

A randomized controlled trial studied 150 mg/day ubiquinol-10 in people with chronic fatigue syndrome for 12 weeks (Research). Researchers assessed autonomic nervous system and cognitive-function measures (Research). A separate male infertility study also used 150 mg/day ubiquinol in oligoasthenozoospermic infertile men and measured sperm parameters and serum testosterone (Research). This dose band appears across more than one research domain, but the outcomes and populations are too different to combine into a single health conclusion (Research) (Research).

Result: Mixed findings
Evidence strength: Limited
Notes / limitations: The same dose level was studied in distinct populations with different endpoints.

200 mg/day oral ubiquinol:

Human studies using 200 mg/day ubiquinol include exercise oxidative-stress research and male fertility research (Research) (Research). In the exercise setting, short-term supplementation before strenuous exercise was reported to reduce oxidative-stress markers and increase plasma nitric oxide (Research). In men with unexplained oligoasthenoteratozoospermia, ubiquinol was studied for sperm density, motility, and morphology (Research). This band supports research interest in both oxidative-stress physiology and reproductive biomarkers, but not a single unified clinical claim (Research) (Research).

Result: Modest improvement
Evidence strength: Limited
Notes / limitations: The evidence is domain-specific and based on surrogate or intermediate outcomes.

200 mg twice daily enteral ubiquinol:

A randomized pilot trial evaluated 200 mg enteral ubiquinol twice daily in severe sepsis or septic shock (Research). This route and setting differ from ordinary supplement use because the study involved acutely ill hospitalized patients (Research). The trial is best interpreted as critical-illness research rather than general immune-health evidence (Research). It adds to dose-context evidence because it used an enteral administration approach in a medically intensive setting (Research).

Result: Inconclusive
Evidence strength: Emerging
Notes / limitations: This dose band should not be generalized to routine wellness contexts.

300 mg/day oral ubiquinol:

A 6-week athletic-performance study used 300 mg/day ubiquinol in young elite trained athletes and reported improved maximum power output (Research). A Parkinson’s disease pilot trial also used 300 mg/day ubiquinol-10 in patients with wearing-off and reported changes in UPDRS outcomes (Research). This dose band appears in both performance and neurological research, but the studies differ sharply in population, outcome, and duration (Research) (Research). The range therefore supports a research-exposure category rather than a single conclusion about benefit (Review).

Result: Mixed findings
Evidence strength: Limited
Notes / limitations: Results depend strongly on population and endpoint.

400 mg/day oral ubiquinol:

A crossover pilot study used 400 mg/day ubiquinol in patients with heart failure with reduced ejection fraction for 3 months (Research). Researchers focused on peripheral endothelial function rather than mortality or hospitalization outcomes (Research). The study reported improvement in endothelial-function measures, supporting interest in vascular physiology (Research). However, the pilot design limits confidence in broader cardiovascular conclusions (Research).

Result: Modest improvement
Evidence strength: Limited
Notes / limitations: The outcome was endothelial function, not a definitive clinical endpoint.

600 mg/day oral ubiquinol:

A phase 2 randomized trial used 600 mg/day ubiquinol in adults with heart failure with preserved ejection fraction, both alone and in combination with D-ribose (Research). The trial reported improvements in KCCQ clinical summary score, vigor, ejection fraction, BNP, and lactate/ATP ratio, but not in 6-minute walk distance (Research). The combination design makes it important to distinguish ubiquinol-alone findings from combination findings (Research). This dose band is among the higher cardiovascular exposures in the locked human evidence library (Research).

Result: Mixed findings
Evidence strength: Moderate
Notes / limitations: Not all clinical or functional endpoints improved.

900–1,500 mg/day oral ubiquinol:

A high-dose phase 1 study evaluated 900, 1,200, and 1,500 mg/day ubiquinol for 14 days in healthy adult male volunteers (Research). The study examined safety, pharmacokinetics, plasma CoQ10, PBMC total CoQ10, and cerebrospinal-fluid-related measures (Research). A separate multicenter phase 2 trial used 1,500 mg/day in multiple system atrophy (Research). These exposures are substantially higher than ordinary dietary intake and higher than many common clinical-trial doses (Review).

Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: High-dose data are specialized and should not be treated as routine-dose evidence.

Key Takeaways from Human Research

• Ubiquinol-specific studies support that oral ubiquinol can raise circulating CoQ10-related measures, but blood exposure depends on formulation and study design (Research) (Review).
• Cardiovascular Health trials show signals in endothelial function and heart-failure outcomes, but the evidence remains limited by pilot designs, short duration, or mixed endpoints (Research) (Research).
• Stress-related fatigue studies reported improvements in chronic fatigue syndrome and mild-fatigue settings, but the evidence is not broad enough to support a general fatigue claim (Research) (Research).
• Muscle Health studies suggest possible effects on peak power and short-term oxidative-stress markers, but exercise research varies by endpoint and population (Research) (Review).
• Neurological Health research includes Parkinson’s disease and multiple-system atrophy trials, but current evidence is exploratory rather than confirmatory (Research) (Research).
• Men’s Health studies have focused on semen parameters, but semen-parameter changes should not be treated as definitive fertility outcomes (Research) (Research).

Origin & Natural Occurrence

Ubiquinol belongs to the coenzyme Q10 system, which is naturally present in human tissues and participates in mitochondrial electron-transfer biology (Review). In this redox system, ubiquinol is the reduced form and ubiquinone is the oxidized form (Review).

CoQ10 is also present in foods, with higher contributions from meat, fish, nuts, and oils than from many fruits, vegetables, cereals, and dairy foods (Review). Ordinary dietary CoQ10 intake has been estimated around 3–6 mg/day, which is far lower than most supplemental ubiquinol studies in the locked human evidence library (Review).

Supplemental ubiquinol is manufactured as a reduced-form CoQ10 ingredient, often in lipid-containing or solubilized preparations because CoQ10 compounds are poorly water-soluble and formulation affects absorption (Review). Human bioavailability research has compared reduced-form ubiquinol with oxidized ubiquinone and reported different blood-exposure profiles in healthy adults (Research).

How It Behaves in the Body

In plain language, ubiquinol is part of a molecule system that helps cells move electrons during energy production and also participates in antioxidant redox cycling (Review). The body can shift CoQ10 between ubiquinol and ubiquinone forms depending on redox conditions, which means the forms are biologically connected rather than completely separate substances (Review).

The mitochondria use CoQ10 in the electron transport chain, a process that helps cells generate ATP, the main cellular energy currency (Review). Ubiquinol is the reduced form, meaning it can donate electrons within redox reactions and is often discussed in relation to oxidative-stress biology (Review).

Human studies show that orally consumed ubiquinol can increase circulating CoQ10-related measures, but the magnitude of change depends on dose, formulation, and baseline characteristics (Research) (Review). A comparative human bioavailability study reported greater absorption of ubiquinol than ubiquinone under the studied conditions, but this does not mean every ubiquinol product or outcome will perform identically (Research).

What is well established is that CoQ10 biology is central to mitochondrial redox function and that oral ubiquinol can change blood CoQ10 measures in humans (Research) (Review). What remains less established is whether those blood-level changes reliably translate into durable clinical benefits across different diseases and populations (Review).

Absorption & Delivery Formats

Oral immediate-release: Most ubiquinol human studies used oral administration, including capsule, liquid, or other oral preparations (Research) (Research). Oral absorption is formulation-dependent because CoQ10 compounds are lipid-soluble and have limited water solubility (Review).

Oral extended-release: The locked evidence library does not contain a clearly identified extended-release ubiquinol human study. Any statement about extended-release ubiquinol would require a source outside the locked library.

Sublingual: The locked evidence library does not contain a sublingual ubiquinol human pharmacokinetic study. Ubiquinol evidence in this report therefore should not be generalized to sublingual delivery.

Transdermal: The locked evidence library does not contain transdermal ubiquinol human absorption data. Claims about transdermal ubiquinol would require additional formulation-specific evidence.

Injectable / IV: The locked evidence library does not contain injectable or intravenous ubiquinol human intervention data. One critical-illness study used enteral ubiquinol, which is gastrointestinal administration rather than injection (Research).

Quick Facts at a Glance

Onset (reported)
Human trials often measured outcomes after weeks rather than hours, such as 2 weeks in exercise oxidative-stress research, 6 weeks in athlete performance research, and 12 weeks in chronic fatigue syndrome or heart-failure research (Research) (Research) (Research). Acute onset for subjective effects is not well characterized in the locked ubiquinol evidence library.

Time to peak (Tmax)
A broader CoQ10 pharmacokinetic review describes slow absorption and reports a time-to-peak context around several hours for CoQ10 preparations (Review). Ubiquinol-specific Tmax can vary by formulation and should not be assumed identical across products (Review).

Half-life (t½)
A CoQ10 pharmacokinetic review reports a half-life context of about 33 hours for CoQ10 preparations, but this is broader CoQ10 evidence rather than a universal ubiquinol-specific half-life for all formulations (Review). Formulation and population differences remain important when interpreting half-life-like estimates (Review).

Typical duration
Ubiquinol-specific human trials in the locked evidence library range from short 2-week exercise studies to 12-week metabolic, fatigue, and heart-failure studies, with longer neurological pilot research also represented (Research) (Research) (Research). This means evidence is stronger for short-to-medium-term outcomes than for long-term population-level outcomes.

Absorption routes studied
The main studied route is oral supplementation, with enteral administration also studied in severe sepsis or septic shock (Research) (Research). The locked evidence library does not support conclusions about sublingual, transdermal, or injectable ubiquinol.

Formulation differences
Human bioavailability research and reviews indicate that CoQ10 absorption is strongly formulation-dependent (Research) (Review). This is especially relevant for ubiquinol because trials used different preparations, including liquid and capsule forms (Research) (Research).

Variability drivers
Potential variability drivers include formulation, dose, baseline CoQ10 status, health condition, study duration, and measured endpoint (Review). These factors help explain why some studies show biomarker changes while clinical or functional outcomes remain mixed (Review).

Tolerance / adaptation
The locked evidence library contains short-term and medium-term safety observations, but it does not establish a clear tolerance or adaptation pattern for ubiquinol effects over time (Research) (Research). Longer studies would be needed to define whether response changes with repeated exposure in different populations.

Evidence strength snapshot
The evidence is strongest for absorption, blood CoQ10 status, and short-to-medium-term physiological endpoints (Research) (Review). Disease-specific evidence is more limited because many trials are small, exploratory, or use surrogate outcomes (Review).

Safety, Interactions & Regulation

Human safety evidence includes healthy-adult studies using 90–300 mg/day and a high-dose study using 900–1,500 mg/day over 14 days in healthy adult male volunteers (Research) (Research). A phase 2 multiple-system atrophy trial also evaluated 1,500 mg/day ubiquinol in a neurological patient population (Research).

General CoQ10 safety reviews describe low toxicity and generally good tolerability, but this broader evidence should not be treated as identical to every ubiquinol formulation, dose, or patient population (Review). The Norwegian Scientific Committee for Food Safety concluded that 100 mg/day CoQ10 from food supplements is unlikely to cause adverse health effects in children above 10 years, adolescents, and adults, but that conclusion concerns CoQ10 supplement risk assessment rather than a disease-treatment use (EFSA).

Interaction evidence in the locked library is limited. Because ubiquinol is commonly studied in cardiovascular and metabolic populations, interaction assessment should be considered especially relevant in people using medications for heart failure, blood pressure, lipids, diabetes, anticoagulation, or complex chronic illness, but the locked library does not provide a definitive interaction map.

In the United States, FDA states that dietary supplements and dietary ingredients are regulated under a framework different from conventional foods and drug products (FDA). FDA’s orphan-drug database lists “ubiquinol, coenzyme Q10, ubiquinone” for pediatric congestive heart failure orphan designation, but the database record states that this designation is not the same as FDA approval for that orphan indication (FDA). FDA warning-letter materials also show that supplements promoted with disease-treatment claims may be treated as unapproved new drugs under U.S. law (FDA).

In the European Union, EFSA evaluated proposed coenzyme Q10/ubiquinone health claims and did not establish the submitted claims as authorized health claims based on the reviewed evidence (EFSA). The EU Register is the appropriate official reference for checking whether specific nutrition or health claims are authorized in the EU framework (EFSA).

Evidence Overview

The overall human evidence for ubiquinol is strongest for absorption, blood CoQ10 exposure, and short-to-medium-term physiological outcomes, while disease-specific evidence is more limited and mixed (Research) (Review). The dominant study types include bioavailability studies, randomized controlled trials, pilot trials, and small condition-specific clinical studies (Research) (Research). Confidence is not higher because studies differ in formulation, dose, population, duration, and outcome selection (Review).

In Cardiovascular Health, ubiquinol has been studied in endothelial dysfunction, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction (Research) (Research). The most informative cardiovascular trial in the locked library is the phase 2 HFpEF study, which reported improvements in several symptoms and cardiac markers but not 6-minute walk distance (Research). This mixed endpoint pattern supports cautious interpretation rather than a broad cardiovascular-effect claim (Research).

In Stress and fatigue-related research, ubiquinol-specific trials reported improvements in chronic fatigue syndrome and mild-fatigue settings (Research) (Research). These findings are relevant but limited because fatigue outcomes can be subjective, population-specific, and sensitive to study design (Review).

In Muscle Health, exercise trials reported changes in peak power or oxidative-stress markers, but reviews of CoQ10 and exercise performance describe variability across studies (Research) (Review). This means the evidence is better described as a physiological signal than as a consistent performance conclusion across all populations (Review).

In Neurological Health, trials in Parkinson’s disease and multiple system atrophy show research interest in neurodegenerative conditions, but the evidence remains exploratory and disease-specific (Research) (Research). In Men’s Health, semen-parameter studies report changes in reproductive biomarkers, but the evidence base does not establish definitive fertility outcomes (Research) (Research).

Future confidence would be strengthened by larger randomized trials, longer follow-up, standardized formulations, predefined clinical endpoints, and clearer separation of ubiquinol-only effects from combination-intervention effects (Review) (Review).

Evidence Confidence Classification

Limited / Mixed is the overall human evidence classification for ubiquinol because it has multiple human studies and pharmacokinetic data, but many condition-specific studies are small, short, exploratory, or inconsistent across endpoints (Research) (Review). The evidence is more mature for absorption and blood CoQ10 status than for durable disease outcomes (Research) (Review). Interventional human studies exist across Cardiovascular Health, Stress, Muscle Health, Neurological Health, Diabetes and Glycemic Control, and Men’s Health, but most areas need larger confirmatory trials before high confidence is justified (Research) (Research).

Similar Ingredients & Comparators

Similar supplement-style ingredients:

• Ubiquinone
• Coenzyme Q10
• Nicotinamide riboside
• Nicotinamide mononucleotide
• L-carnitine
• Alpha-lipoic acid
• Riboflavin
• PQQ
• Creatine
• D-ribose
• Astaxanthin

Medical / pharma comparator categories:

• Heart-failure medications
• Lipid-lowering medications
• Diabetes medications
• Antioxidant-support research interventions
• Fertility-treatment categories
• Neurological disease-modifying or symptomatic therapies
• Critical-care supportive therapies

Combination Context

Ubiquinol + D-ribose:
A phase 2 HFpEF trial studied ubiquinol, D-ribose, and their combination to evaluate symptom, cardiac-function, and metabolic markers in heart failure with preserved ejection fraction (Research). The study reported improvements in several endpoints but not 6-minute walk distance, so the combination context remains mixed rather than definitive (Research).

Ubiquinol + standard heart-failure care:
Heart-failure studies generally evaluated ubiquinol in patient populations already receiving clinical care rather than as a stand-alone replacement for medical treatment (Research) (Research). The research examined endothelial function, symptoms, cardiac markers, and exercise capacity, but it does not support replacing standard therapy (Research).

Ubiquinol + enteral critical-care nutrition context:
In severe sepsis or septic shock, ubiquinol was administered enterally in a pilot trial, placing it in a medically supervised critical-care context rather than an ordinary supplement-combination context (Research). The evidence remains exploratory and should not be generalized to routine immune-support combinations (Research).

FAQ

What is ubiquinol?

Ubiquinol is the reduced form of coenzyme Q10, a lipid-soluble compound involved in the body’s CoQ10 redox system (Review). It occurs endogenously in human tissues and is also related to CoQ10 found in foods and supplements (Review). Human research has studied ubiquinol mainly for absorption, fatigue-related outcomes, cardiovascular physiology, exercise physiology, neurological conditions, metabolic markers, and male reproductive biomarkers (Review).

What does human research study ubiquinol for?

Human research studies ubiquinol for bioavailability, Cardiovascular Health, Stress-related fatigue, Muscle Health, Neurological Health, Diabetes and Glycemic Control, Men’s Health, and limited critical-illness contexts (Research) (Research). The studies include randomized trials, pilot trials, crossover studies, and pharmacokinetic studies (Research). The evidence is not equally mature across domains, with absorption and short-term physiological endpoints better characterized than long-term clinical outcomes (Review).

What are the best-supported uses?

The best-supported area is not a disease use, but the finding that oral ubiquinol can increase circulating CoQ10-related measures in humans (Research). Ubiquinol-specific trials also provide limited supportive evidence in fatigue, exercise physiology, endothelial function, and selected heart-failure endpoints (Research) (Research). These studies do not establish ubiquinol as a treatment, prevention, or cure for any condition (FDA).

Where is evidence mixed or limited?

Evidence is mixed or limited in Cardiovascular Health, Neurological Health, Muscle Health, Diabetes and Glycemic Control, and Men’s Health because studies differ in size, design, formulation, population, and outcome type (Review). The HFpEF trial reported improvements in several markers but not 6-minute walk distance, illustrating how findings can vary by endpoint (Research). Neurological studies are exploratory and disease-specific rather than confirmatory (Research) (Research).

How quickly does ubiquinol act?

The locked human evidence library does not establish a clear rapid-onset effect for ubiquinol. Most outcome studies measured changes after weeks, such as 2 weeks, 6 weeks, 12 weeks, or longer disease-specific trial periods (Research) (Research) (Research). CoQ10 pharmacokinetic evidence indicates slow absorption, with time-to-peak context occurring over several hours rather than immediately (Review).

What affects absorption and variability?

Absorption and variability are affected by formulation, lipid solubility, dose, baseline status, and study population (Review). A comparative human bioavailability study reported greater absorption of ubiquinol than ubiquinone under the studied conditions (Research). These findings mean results from one ubiquinol preparation should not automatically be generalized to every formulation (Review).

Is tolerance reported?

The locked evidence library does not establish a clear tolerance pattern for ubiquinol. Short-term safety and pharmacokinetic studies evaluated repeated dosing, including 90–300 mg/day over 4 weeks and 900–1,500 mg/day over 14 days (Research) (Research). These studies provide tolerability context but do not define whether effects diminish, persist, or adapt over longer periods in different populations.

Why do studies disagree?

Studies may disagree because ubiquinol trials use different doses, formulations, populations, endpoints, and durations (Review). Some trials measure blood levels or biomarkers, while others measure symptoms, exercise outcomes, endothelial function, or disease scales (Research) (Research). These differences can produce positive biomarker findings without consistent clinical-outcome findings (Review).

What ingredients is ubiquinol commonly combined with and why?

In the locked evidence library, the clearest studied ingredient combination is ubiquinol + D-ribose in heart failure with preserved ejection fraction (Research). That study examined symptom, cardiac, and metabolic markers, but the results were mixed across endpoints (Research). Other contexts involve ubiquinol alongside standard medical care or enteral critical-care administration rather than ordinary consumer supplement stacks (Research) (Research).

What foods naturally contain ubiquinol?

The locked evidence library supports food-source discussion for CoQ10 broadly, not isolated food-specific ubiquinol content. CoQ10 is found in foods such as meat, fish, nuts, and oils, while many fruits, vegetables, cereals, and dairy foods generally contain lower amounts (Review). Average dietary CoQ10 intake is much lower than the supplemental ubiquinol doses used in most clinical studies (Review).

How is ubiquinol regulated?

In the United States, ubiquinol-containing dietary supplements are regulated under FDA’s dietary-supplement framework rather than as approved drugs for disease treatment (FDA). FDA’s orphan-drug database includes a listing for “ubiquinol, coenzyme Q10, ubiquinone” related to pediatric congestive heart failure, but the record indicates that the designation is not FDA approval for that orphan indication (FDA). In the European Union, EFSA evaluated proposed coenzyme Q10/ubiquinone health claims and did not establish the submitted claims as authorized health claims based on the evidence reviewed (EFSA).

Resources

Hosoe et al. — PubMed — https://pubmed.ncbi.nlm.nih.gov/16919858/
Failla et al. — PubMed — https://pubmed.ncbi.nlm.nih.gov/24979483/
Alf et al. — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC3661336/
Mizuno et al. — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC7352232/
Pierce et al. — PubMed — https://pubmed.ncbi.nlm.nih.gov/35644694/
Mitsui et al. — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC10225719/
Mantle & Dybring — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC7278738/
FDA Dietary Supplements — FDA — https://www.fda.gov/food/dietary-supplements
EFSA CoQ10 Claims Opinion — EFSA — https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2010.1793
EU Register of Nutrition and Health Claims — European Commission — https://ec.europa.eu/food/food-feed-portal/backend/claims/files/euregister.pdf

More from the Supplement Ingredients & Medical Ingredients Encyclopedia​